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ABSTRACT
C/EBP transcription factors have been recognized as key regulators of cellular

differentiation in a variety of cells, including adipocytes, hepatocytes, granulocytes and

macrophages. A growing literature also suggests an important role for C/EBP family
members in the growth and differentiation of osteoblasts. To better comprehend the role
of C/EBP in osteogenesis, a transgenic mouse model has been generated in which the

function of C/EBP in cells of the stromal and osteoblast lineage has been blocked by

overexpression of a dominant negative isoform of C/EBP/3, known as p20C/EBP/3.
Preliminary studies of these p20C/EBP/3 transgenic mice demonstrated varying

degrees of osteopenia. Although only three out of the four lines of transgenic mouse
models created exhibited an osteopenic bone phenotype, all four possessed alterations in
osteoblastic marker gene expression. The analysis of such markers in femurs and calvaria

of transgenic mice indicated two possible sites of action at which C/EBP/3 affected the
osteoblast lineage. The first site of action occurred late in osteoblast differentiation,
manifested by a decrease in terminal markers of osteoblastic differentiation such as
osteocalcin and pOBCol 2.3 GFP. The latter is a transgenic reporter of osteoblast
differentiation in which the visible GFP protein is expressed under control of a 2.3 kb

Colalpromoter construct. The second site appears to be in early osteoblast differentiation
characterized an increase in early differentiation markers such as bone sialoprotein (BSP)

and alkaline phosphatase. These preliminary studies have also shown an increase in cell
number in transgenic mouse stromal cells cultures. The same phenomenon was observed
in primary cell cultures, with an increase in cell number in the TG cultures after day 7,
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reaching a plateau at day 15. It was unknown if the increase in cell number in TG
cultures was due to an increase in cell proliferation or a decrease in cell apoptosis.

Therefore, in the present study, primary osteoblast and BMSC cultures from TG
mice were be used to measure proliferation and apoptosis in the early stages of culture.

Studies were performed on a pOBCol3.6-GFP genetic background to provide a real-time

marker of the stromal-osteoprogenitor pool and to allow changes in this cell population to
be specifically tracked within a heterogeneous population of cells. Proliferation and

apoptosis were assessed by flow cytometry analysis. In order to measure cell
proliferation, cells were pulsed with BrdU, because it can be incorporated into DNA in

place of thymidine. Cells were pulsed in a range from 2 to 12 hours, and detected using a
monoclonal antibody against BrdU. Apoptosis was assessed using annexin V, a marker

of early apoptosis, and 7AAD, a marker of late apoptosis, as measured by flow cytometry

analysis.

By analyzing the results of these experiments we will be determine if the role of e
C/EBP transcription factors in early osteoblast differentiation and whether they act to

increase proliferation or as a protective factor decreasing the number of cells undergoing

programmed cell death.
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Introduction

Objective ofResearch

In order to better understand the process of bone formation, both in health and
disease, it is necessary to understand the molecular and genetic mechanisms

underlying this process. The precise molecular events occurring during osteoblast
differentiation are not yet understood. A more thorough understanding of osteoblastic
differentiation and proliferation will be required for the elimination of certain bone

diseases and will improve our understanding of orthodontic tooth movement.
With the objective of over-expressing a dominant negative C/EBP to asses the

role of C/EBP in bone, four lines of mice carrying the pOBCol3.6 FLp20C/EBPI3

transgene (a dominant negative form) have been established by pronuclear

microinjection and designated as lines 00-59, 50-10, 63 and 65. The only difference
between these four lines is the position of the transgene within the mouse genome.
These lines were subsequently crossed with homozygous POBCol2.3-GFP mice.
These mice, expressing a GFP fluorescent reporter, were developed at the University

of Connecticut and express the osteoblast-specific GFP marker which allows for in
vivo imaging of the terminal stages of osteoblast differentiation. Initial work in our

lab on these four lines of p20C/EBP[3 transgenic mice has shown varying degrees of

osteopenia secondary to reduced bone formation. It was demonstrated that there were
alterations in osteoblastic marker gene expression with an overall increase in BSP

expression and an overall decrease in osteocalcin and POBCol2.3-GFP expression. It
is important to note that these latter two markers are in fact terminal markers of

osteoblastic differentiation. An overall decrease in POBCol2.3-GFP expression in

vivo was also noted in these transgenic lines. These preliminary studies help illustrate

how C/EBP transgenic factors are required either for osteoblast differentiation or for
the maintenance of the osteoblast phenotype. In order to better understand the role of
C/EBP’s during osteoblast proliferation, the previously mentioned lines of mice were

crossed with pOBCol3.6-GFP mice, an early marker of osteoblast differentiation.

Using this model the expression of GFP in our TG cultures should be directly
correlated with the expression of our transgene, since they are driven by the same

promoter. To be able to identify and quantify the number of cells undergoing

proliferation a flow cytometry analysis using BrdU incorporation into the cellular

DNA was undertaken. The amount of BrdU labeling was analyzed by flow cytometry
analysis. At the same time, using a two color analysis, GFP was determined. With this

design we were be able to determine the cells that not only are undergoing

proliferation, but those that were expressing the p20C/EBP transgene. We also

attempted to determine the apoptosis rate occurring in primary calvarial cells overexpressing C/EBP[3. To identify the number of cells undergoing programmed cell
death a 7AAD-Annexin V incorporation assay was used followed by flow cytometry

analysis in order to measure incorporation of these apoptotic markers. By identifying
the cell responses accounting for the increases in cell number in early TG cultures, we
would improve our understanding of the role of C/EBP in the regulation of

pluripotent progenitor pools and in early osteoblast differentiation.

Background
Osteoblasts are the primary bone-forming cells in the body. Their presence and

activity are essential for acquiring and maintaining normal bone mass. It is being
recognized that impaired generation of bone cells, either due to an underperforming
lineage or to a diversion of the lineage to other cell types, is a primary cause for
diminished bone mass.[ 1 Identifying factors that regulate osteoblast differentiation will

be necessary to understand diseases of bone and for designing effective therapeutic

strategies. 1 ]
Osteoblast precursors are recruited from a multipotential mesenchymal progenitor
that can give rise to several differentiated cell phenotypes including fibroblasts,

chondrocytes, adipocytes and osteoblasts. 1 ] Undifferentiated osteoprogenitors are
present in the bone marrow and periosteum. These undifferentiated osteoprogenitor cells

eventually differentiate into preosteoblasts, osteoblasts and finally osteocytes (figure 1)
Unfortunately, the differentiation and ultimate fate of these osteoprogenitor cells is
determined and influenced by a complex and still poorly understood interaction of

hormones and local factors.

C/EBP and Cellular Differentiation

The C/EBP family is known to be involved in the regulation of cell growth and
differentiation of several cell types. Common structural features of these proteins are

highly conserved DNA binding and leucine zipper dimerization domains at the carboxyl
terminus and divergent amino termini containing regulatory and transactivation

domains[2, 3] C/EBPI3 has been linked to hepatocyte specific gene regulation because it
shows high expression in liver cells [4]and binds to regulatory elements in the promoter
of liver specific genes. In addition it has been suggested that C/EBPI3 contributes in the

regulation of the acute phase response of the liver. Lately, it has become clear that

C/EBP3 also play a role in other tissues. Results derived from experiments in cell culture
and with knockout mice have demonstrated that this protein is essential for lymphocyte
and adipocyte differentiation [5, 6] The role of different C/EBP proteins during

adipocyte differentiation is thought to follow a sequential model in which C/EBP6 and

C/EBP[3 precede expression of C/EBPa which functions to inhibit proliferation and
promote terminal differentiation. In fact expression of C/EBPa is primarily restricted to

highly differentiated cells such as hepatocytes, adipocytes and type II cells of the

lung.[7]. This sequential expression of C/EBP isoforms, together with the fact the
C/EBPa promoter contains a C/EBP response element, has led to the idea that C/EBP[3

can activate the expression of the C/EBPa promoter during differentiation processes such
as adipose conversion.

A large body of literature suggests important roles for C/EBP family members in
growth and differentiation of osteoblasts. In primary rat osteoblast cultures, C/EBP[3 and
C/EBP6 are abundantly expressed in proliferating cells, decline during the mid-stage of

differentiation, and then subsequently increase at late stages of differentiation. C/EBP[3
and C/EBPi can also act synergistically with Runx2/Cbfal, a transcription factor and
nuclear matrix binding protein, to enhance osteocalcin transcription in cell culture

systems. [8]Correlating C/EBP3 and 5 function with Runx2 presents a critical link
between C/EBP factors and osteoblast differentiation given that Runx2/Cbfal is essential

for osteoblastic response to extracellular matrix signals and is needed for the expression
of genes associated with osteoblast differentiation. [9] Several key studies have
established that Runx2 is required for both in vivo bone formations as well as for

osteoblast differentiation. 10] It has also been demonstrated that forced expression of
Runx2 in non-osteoblastic cells leads to osteoblast-specific gene expression. 11]

Furthermore, Runx2-defficient mice completely lack bone formation, due to an absence
of osteoblasts, demonstrating that Runx2 is an essential factor for osteoblast
differentiation. [12] Also, humans with cleidocranial dysplasia, an autosomal dominant
condition characterized by phenotypic changes in skeletal patterning and growth, have

been shown to have deletions within the human Runx2/Cbfal gene [13]. The C/EBP

family has also been shown to play vital roles in regulating adipocyte commitment,
differentiation and gene expression. C/EBP]3 and C/EBP5 have been shown to be

expressed very early in the pathway from multi-potential progenitor cells to adipocytes.

[5, 6] C/EBP]3 and C/EBP then induce the expression of C/EBPa and PPAR which
direct the expression of terminal adipocyte marker genes.[ 14] Disruption of the C/EBPa

15] C/EBP]3 and C/EBP5 genes [16] prevented normal development of adipose tissue.
The role of C/EBP transcription factors in adipogenesis is important when appreciating
that osteoblasts and adipocytes share common pluripotent progenitor cells. It has been

shown that an inverse relationship exists between the differentiation of adipocytes and
osteoblasts in rats. [17] Hopefully, the role of C/EBP’s in adipogenesis can provide some

insight into their potential role in regulating osteogenesis.

CCAAT/Enhancer-Binding Proteins (C/EBP)
The C/EBP’s are a family of transcription factors that function in tissue

differentiation, healing, immune response and tissue metabolic functions. [18]There are

currently six members of the C/EBP family that have been isolated and characterized:
C/EBP -a,

-13, -5, -/, -, and-. [19] The majority are expressed in liver, spleen and

adipocytic tissues. [8] The C/EBP are classified as members of the basic leucine zipper

(bZIP) transcription factor family [Fig 2]. [7] They are structurally related to each other,
each consisting of an amino terminal transactivation region, a central basic DNA-binding
domain, and a Carboxy-terminal dimerization interface termed the leucine zipper. 18]
The terminal leucine zipper mediates dimerization between C/EBP polypeptides.
This dimerization is required for DNA binding and for the activation of transcription in

target genes. [20] (Fig 3) C/EBP proteins can form either homodimers or heterodimers
with one another, as well as with other members of the bZIP family. They can also form

protein-protein interactions with non-bZIP transcription factors. [21 The central DNA
binding domain is highly conserved and rich in basic amino acids. The amino-terminal
region has amino acid sequences that are unique to each C/EBP member and are critical
for transcriptional activity. [20]

C/EBP3 mRNA has three in-frame AUG start codons which initiate the
translation of three protein isoforms of 38 kDa, 35kDa and 20 kDa. [9] The larger

products, p38 and p35C/EBP]3 (originally called LAP) contain the N-terminal
transactivation domain and function as transcriptional activators. [22] The 20 kDa
isoform (originally LIP) lacks this N-terminal transactivation domain but contains the Cterminal bZIP domain; p20C/EBP[3 therefore acts as a dominant negative regulator of
C/EBP function.

[22]. This isoform can also arise by a proteolytic cleavage of full length

C/EBP]3 that is C/EBPa independent. [23]
A number of studies have suggested important roles for members of the bZip
transcription factor superfamily in regulating skeletal development. Wang et al. reported
that c-fos null mice exhibit osteopetrosis and a failure of tooth eruption due to a lack of

osteoclasts[ 15]. Two models of bZip overexpression have been reported that result in
osteosclerosis due to increased bone formation; overexpression of AFosB, a naturally

occurring splice variant of FosB[24], and overexpression of Fra-1 [25], the product of the
c-fos-related fsll gene. The overexpression of AFosB with the NSE promoter also
resulted in a decrease in adipogenesis, leading to speculation that diversion of pluripotent

progenitors from adipoctye to osteoblast commitment could be the cellular mechanism
responsible for the osteosclerosis. However, a follow-up study in which AFosB was

targeted with the osteoblast-specific 0(2 promoter resulted in an osteopetrotic phenotype
with normal adipogenesis, indicating a cell autonomous action of AFosB on osteoblast

function[26]. Interestingly, in this study AFosB and the further truncated isoform
A2AFosB were found to interact with C/EBPI3 and alter its ability to bind to a C/EBP
consensus sequence. This resulted in an inhibition of adipogenesis in multipotent ST2

cells but not in the committed pre-adipocytic line 3T3-L1. This observation was

interpreted as evidence that the interaction of these transcription factors at a very early
stage could prevent commitment to the adipocyte lineage.

Recently, a role in osteoblast differentiation has been demonstrated for ATF4, a
member of the CREB-ATF transcription factor family. Loss of ATF4 function by gene
ablation in mice resulted in osteopenia associated with a failure of terminal differentiation

and reduced type I collagen protein synthesis[27]. This study identified ATF4 as a

substrate for RSK2, a growth factor regulated kinase. Loss of RSK2 function also

resulted in a low bone mass phenotype[27]. In subsequent work, it was shown that over-

expression of ATF4 in non-osteoblastic cells can induce osteoblast-specific gene
expression[28]. Further, a cooperative interaction between ATF4 and Runx2 results in

high level expression of the terminal osteoblast marker gene OC[29].

C/EBP transcription Factors. Role in Osteoblast Differentiation and Function

A number of reports have supported a positive role for C/EBP in osteoblast
differentiation. C/EBP’s as well as bone morphogenetic proteins (BMP) play essentials

roles in mammalian cell differentiation by shaping adipogenic and osteoblastic lineages.

Recent evidence suggested that adipocytes and osteoblast share a common mesenchymal
precursor cell phenotype, Using the C2C 12 engineered pluripotent cell line (myocyte,

adipocyte, osteoblast), Fux et al. [30] found that C/EBPa may differentiate cells into
either osteoblasts or adipocytes, depending on the level of expression. With low levels of

expression osteoblasts were generated, but when maximum levels of C/EBPa were

expressed adipocytic differentiation occurred. In these same cells Gu [31 overexpressed
BMP7 and observed a shift in the differentiation pathway from myoblast to osteoblast. It

was observed that the level of Runx2 mRNA, a bone specific transcription factor was

also stimulated. Using real time PCR the level of C/EBP5 were increased but it was not
noticed any changes on the level of C/EBP were observed. In a recent report McCarthy

[32], observed that the 3’ proximal region of the C/EBPi gene promoter contains a
binding sequence for Runx2, indicating a possible regulation of C/EBP5 expression by
Runx2. The effects of C/EBPI3 and p20C/EBPI3 on adipocyte and osteoblast
differentiation were studied by Hata et al. [33] in C3H10T1/2 cells. In this model, the

expression of p20C/EBPI3 blocked adipocyte differentiation and, in cooperation with

Runx2, led to an increase in osteoblast differentiation.
Preliminary studies done in our laboratory have seen two possible sites of action
for C/EBP[3 during osteoblast differentiation; one occurring late in maturation as seen by
a decrease in osteocalcin and POBCol2.3-GFP and the second occurring early in

osteoblast differentiation manifested by an increase in alkaline phosphatase and bone

sialoprotein (Figure 4).

C/EBP Transcription Factors and Proliferation

Recent evidence suggests that cell proliferation can be regulated by members of
the C/EBP family. C/EBPa, the first member of the family to be identified, has been
associated with an antimitotic activity.[34]. Some reports have been published showing

that C/EBPa can interact with p21, a potent inhibitor of cyclin depedent kinases (CDKs),

the enzymes that are crucial for the orderly progression of the cell cycle. It has been

found that C/EBPa mediated growth arrest occurs through protein interaction and is

independent of its transcriptional activity.[35, 36].

In a recent study published by Wang it was showed that C/EBPa interacts
directly with cdk2 and cdk4, arresting cell proliferation by inhibiting these cells kinases.

As expected, the activities of cdk2 and cdk4 are increased in C/EBPa knockout mice,
resulting in enhanced proliferation. [37]

C/EBPfl and CellProliferation
A number of studies have reported an effect of C/EBP[3 on cell proliferation, in a
study done by Buck using HepG2 hepatocarcinoma cells, it was seen that expression of
full-length C/EBPB caused arrest of cells at the G1/S boundary. This effect required the
leucine zipper and N-terminal transactivation domains, p20C/EBP3 having a dominant

negative transcriptional activity had opposite effects to the ones observed with the full

length protein. A similar anti-proliferative effect of C/EBPB was observed in a study
done by Zhu in keratinocytes [38]. In primary mouse fibroblasts, over-expression of
some oncogenes, including Ras v2, causes cells to exit the cell cycle and enter G1 phase o

[39].
Contrary to these observations it has been observed that, C/EBPB appears to be a
positive regulator of the cell cycle in mammary epithelial cells. In an experiment done by

Seagroves, on C/EBP3 null mice it was observed that mammary epithelium fail to
proliferate, and resulted in poor ductal morphogenesis with inability to lactate [40, 41 ]].
The p20C/EBP isoform has been also correlated with hyperproliferation and

transformation in mammary epithelial cells. Transgenic mice with overexpression of

p20C/EBPB in mammary tissue show focal and diffuse alveolar hyperplasia and
occasional neoplasias, and invasive and noninvasive carcinomas [42].
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C/EBP Transcription Factors and Apoptosis

Substantial evidence supports a role for C/EBPg and other family members in the control

of apoptotic cell death. The stimuli that initiate the apoptotic process include
extracellular signals such as the Fas ligand. Stimulation of the Fas pathway in response
to Fas ligand or agonistic anti-Fas receptor antibodies results in recruitment of proteins

that form the death inducing signaling complex (DISC) including procaspase 8 and Fasassociated Death Domain (FADD). Formation of the DISC is followed by activation of

procaspase 8, which cleaves Bid, a proapoptotic member of the Bcl 2 family, resulting in
release of cytochrome c from the mitochondria, activation of caspase 3, and cleavage of

cellular substrates, cellular breakdown and ultimately cell death.

Several inhibitors of

mitochondrial cytochrome c release including Bcl-2 and Bcl-x mediate resistance to Fasinduced cell death. C/EBP]3 has been linked to apoptotic targets in the liver; in a recent

publication[43] apoptosis induced by an activating anti-Fas antibody was greatly reduced
in hepatocytes of C/EBPI3 null mice, suggesting a anti-apoptotic role in these cells. This

decrease was associated with a 10-fold increase in expression of Bcl-x protein, an anti-

apoptotic member of the Bcl family [43]. In Neuro2A cells, C/EBPI3 was shown to
enhance apoptosis via activation of p53 and the cdk inhibitor p21 [44].

Contrasting these studies, C/EBPB can also act as an inhibitor of apoptosis. In a

publication by Stemeck and Zhu [45] C/EBPI3 knockout mice exhibited increased
apoptosis in epidermal keratinocytes in response to carcinogen treatment and are

completely resistant to carcinogen induced skin tumorigenesis. Their findings showed
that C/EBP3 exerts an essential, keratinocyte-intrinsic role in cell survival in response to
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carcinogen treatment. The elimination of C/EBPI3 in keratinocytes is sufficient to confer

complete resistance of the skin chemical carcinogenesis. C/EBPI3 appears to inhibit
apoptosis in different ways. A study by Buck suggested that phosphorylation of C/EBP3

by RSK (ribosomal protein $6), enzyme responsible for propagation of the EGFR
(epidermal growth factor receptor), prevents activation of procaspases 1 and 8 and
therefore prevents apoptosis [46]. Another mechanism by which C/EBP[3 might prevent

programmed cell death is by promoting cell survival through enhanced expression of
survival factors. For example, Myc/Raf transformed macrophages required C/EBPI3

expression to prevent cell death. This effect was mediated by C/EBPg-dependent
expression of IGF-I, an autocrine survival factor for these cells [47].

12

BrdU

The immunofluorescent staining of incorporated bromodeoxyuridine (BrdU) and
flow cytometric analysis provide a high resolution technique to determine the frequency
and nature of individual cells that have synthesized DNA. In this method, BrdU (an

analog of the DNA precursor thymidine) is incorporated into newly synthesized DNA by
cells entering and progressing through the S (DNA synthesis) phase of the cells cycle

(Fig 7).[48] The incorporated BrdU is then detected with specific anti-BrdU fluorescent
antibodies using flow cytometry. Often, staining with a dye that binds to total DNA such
as 7-amino-actinomycin D (7-AAD) is coupled with immunofluorescent BrdU staining.

With this combination, two-color flow cytometric analysis permits the enumeration and

characterization of cells that are actively synthesizing DNA (BrdU incorporation) in
terms of their position in the cell cycle (i.e., G0/G 1, S, or G2/M phases defined by 7-

AAD staining intensity as an indicator of ploidy)[49]
Prolonged exposure of cells to BrdU allows for the identification and analysis of
actively cycling, as opposed to non-cycling, cell fractions. Pulse labeling of cells with
BrdU various time points, permits the determination of cell-cycle kinetics.[50]
Annexin V

Apoptosis is characterized by a variety of morphological features such as loss of
membrane asymmetry and attachment, condensation of the cytoplasm and nucleus, and
intemucleosomal cleavage of DNA. One of the earliest indications of apoptosis is the
translocation of the membrane phospholipids phophatidylserine (PS) from the inner to the
outer leaflet of the plasma membrane. Once exposed to the extracellular environment,
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binding sites on PS become available for Annexin V, a 35-36 KDa, Ca / dependent,

phospholipd binding protein with a high affinity for PS (Fig.7).[51 ]
The translocation of PS precedes other apoptotic processes such as loss of plasma
membrane integrity, DNA fragmentation, and chromatin condensation. As such,
Annexin V can be conjugated to biotin or to fluorochrome such as FITC, PE, APC, Cy5,
or Cy5.5, and used for the easy flow cytometric identification of cells in the early stage of

apoptosis.

Because PS translocation also occurs during necrosis, Annexin V is not an
absolute marker of apoptosis. Therefore, it is often used in conjunction with vital dyes
such as 7-amino-actinomysin (7AAD) or propidium iodide (PI), which bind to nucleic

acids, but can only penetrate the plasma membrane when membrane integrity is breached,
as occurs in the later stages of apoptosis or in necrosis (Fig.

8).[52]

Cells that are negative for Annexin V and the vital dye have no indications of

apoptosis" PS translocation has not occurred and the plasma membrane is still intact.

On the other hand cells that are Annexin V-positive and vital dye-negative,
however are in early apoptosis as PS translocation has occurred, yet the plasma
membrane is still intact.
Cells that are positive for both Annexin and the vital dye are either in the late

stages of apoptosis or are already dead, as both PS translocation and the loss of plasma
membrane integrity have occurred. When measured over time, Annexin V and vital dye
can be used to monitor the progression of apoptosis: from cell viability, to early-stage

apoptosis, and finally to late-stage apoptosis and cell death.[53]

14

Rationale

Substantial evidence has been generated to support that pOBCol3.6-targeted

p20C/EBPI3 expression increases the availability of multipotent progenitor cells to the
osteoblast and adipocyte lineage pathways. From our preliminary studies we know that

pOBCol3.6-targeted p20C/EBPI3 affect the osteoblastic lineage in two different locations,
the first one occurring late in differentiation, as shown by the decrease in terminal
markers as osteocalcin and pOBCol2.3-GFP, suggesting a late differentiation arrest. The

second site of action occurs early in differentiation, as seen by an increase in alkaline

phosphatase (Alk-phos) and bone sialoprotein (BSP), as well as an increase in cell
number in the TG cultures.

We have taken advantage of our ex vivo model systems to perform mechanistic
studies on the role of cellular proliferation and apoptosis in regulating the pool of

progenitor cells. The advantage of this approach is that it should be more physiologically
relevant than the use of osteoblastic or multipotent immortalized cell lines, which may
not faithfully reflect lineage progression pathways that occur in vivo. Moreover, primary

calvarial cell cultures represent well-studied and widely accepted models of lineage

progression in vitro, exhibiting the full range of differentiation from pluripotentprogenitor cell to terminally differentiated cell. A major limitation of this approach is the
heterogeneity of the culture system, making it difficult or impossible to ascribe an
observed effect to a specific cell population.

To circumvent this problem, these

experiments will be performed in a genetic background harboring pOBCol3.6-GFP to

provide a real-time fluorescent marker of the pluripotent osteoblast lineage.
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We have focused primarily on flow cytometry-based methods for measuring
cellular proliferation and apoptosis, allowing us to compare changes not only between

WT and TG cultures, but also between the GFP-positive and GFP-negative cell
populations. Our data suggests that GFP-positive cells at early stages of culture represent

pluripotent progenitor cells capable of giving rise to adipocytes or osteoblasts. Following
commitment to the osteoblast lineage, GFP-positive cells express early osteoblast

markers such as AP and BSP.

GFP expression then persists alongside late osteoblast

differentiation markers such as OC, DMP-1 and pOBCol2.3-GFP [1, 54]. Importantly,
since GFP and the p20C/EBPI3 transgene are under control of the same pOBCol3.6

promoter, GFP will serve as a visual surrogate marker to indicate which cells are
expressing the p20C/EBPI3 transgene. This allowed us to track cell-autonomous effects
on cell proliferation and/or apoptosis by differential analysis of transgene effects (WT vs.

TG) in GFP-positive and GFP-negative populations.
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Hypothesis

Primary cells from TG mice show enhanced or prolonged proliferation relative to
WT cells.
Primary osteoblast from transgenic mice show enhanced apoptosis compared to
WT cells
Specific Aims
1. Flow cytometry analysis of proliferation in primary osteoblasts will be assessed

by:
BrdU labeling

Analysis of proliferation specifically in TG expressing cells using a
surrogate GFP marker

pOBCol3.6-GFP (early osteoblast marker, p20 TG promoter)
2. Analysis of cells undergoing apoptosis will be assessed by:

Incorporate Annexin V and 7-AAD and flow cytometry analysis
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Experimental design, procedures, and methods
Creation ofFLA G-taggedp2OC/EBPfl transgenic mice

In order to identify the cells that express the C/EBP transgene, an amino-terminal
FLAG epitope was incorporated into the p20C/EBP]3 construct. This allows the C/EBP
transgene to be detected by Western bloting against the FLAG epitope and

immunocytochemistry using the M2 FLAG antibody. We can therefore discriminate
between p20C/EBP[3 and endogenously occurring C/EBP isoforms. The dominant

negative function of p20C/EBP]3 is not altered by the incorporation of the FLAG epitope
due to the modular nature of transcription factors. The FLAG p20C/EBP]3 construct was
created by PCR using the CMV-LIP plasmid as a template and confirmed by sequencing.

Experiments also confirmed the FLAG-tagged p20C/EBP[3 exhibits the expected DNA
binding, nuclear localization, and dominant negative function.
Targeting of FLp20C/EBP]3 to osteoblastic cells:

A pOBCo13.6-FLp20/C/EBPI3 construct was used to target expression of
FLp20C/EBPI3 throughout the osteoblastic lineage. PCR3.1-FLp20/C/EBP]3 was
digested with HindIII and XbaI and the resulting FLp20/C/EBPI3 fragment was subcloned
into an intermediate Cla vector which contains a polylinker and the bovine growth

hormone (bGH) polyadenylation sequence flanked by two ClaI sites. Following

digestion of ClaI, the FLp20/C/EBPI3-bGH cassette (792 bp) was isolated and subcloned
into pBCSK+ColInt5.2Xba, which contains a ClaI site downstream of the 3.6 kb Collal

promoter and 1.6 kb Collal first intron. Clones containing FLp20/C/EBPI3 in the correct
orientation were identified using asymmetric restriction sites.
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Because there is differential utilization of Col l a l promoter elements as the cell
progresses through differentiation, FLp20C/EBP]3 expression can be targeted toward cells
at multiple stages of the osteoblast lineage, pOBCol3.6GFP has been reported as an early

marker of the osteoblast lineage, being expressed in early pluripotent progenitor cells,
while pOBcol2.3GFP expression is restricted more to differentiated osteoblasts [55].

Therefore, FLp20C/EBP[3 driven by pOBCol3.6 was used to target expression broadly
throughout the osteoblast lineage. Heterozygous transgenic and wild type mice were
crossed with homozygous pOBCol3.6-GFP reporter mice, providing us a osteoblast

lineage that is also a surrogate reporter of the early p20C/EBP]3 transgene expression,
since the p20C/EBP transgene and GFP are driven by the same promoter in the resulting

transgenic offspring.

Preparation of Transgenic FLp2OC/EBPfl Overexpressing Mice

A pronuclear microinjection technique of pOBCol3.6-FLp20C/EBPI3 was used to
prepare transgenic CD-1 mice that overexpress FLp20C/EBP[3. A dot blot analysis of tail
snip DNA from potential founders was screened by using a probe directed against the
human growth hormone polyadenylation site, which is cloned downstream of

p20C/EBP3. Mice that screened positive for the human growth hormone 3’-UTR were
confirmed by PCR using a 5’-primer directed against the Collal first intron (5’-

ACCCTCCTCCATTTTAGCC-3’) and a 3’-primer directed against the FLAG epitope

(5’-CATCGTCGTCGTCCTTCTAGTC-3’). Four transgenic founders (2 male, 2 female)
were obtained and bred with wild type CD-1 mice to establish transgenic lines. Progeny
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are screened for the presence of the transgene at the time of weaning by tail snip, DNA

extraction and PCR. The four transgenic lines are: 00-50-9, 00-50-10, 00-63 and 00-65.

Primary cell culture model
Transgenic pOBCol3.6-FLp20 C/EBPI3 mice were crossed with homozygous

pOBCol2.3GFP mice. The GFP, or green fluorescent protein, provides an osteoblastspecific marker which can be visualized and photographed in living cells under a
microscope.
Calvaria, comprising the frontal and parietal bones, were dissected from six to

eight week old wild type and pOBCol3.6-FLp20 C/EBPI3 transgenic mice. Through a
2
series of five digestions, primary cells were isolated and plated in 8cm wells. Cells were

counted and plated to a density of 17,500cells/cm2 for a total of 140,000 cells per well.
Cultures were fed on the second and fifth day with DMEM (Dulbecco’s modified Eagle
Medium ) media supplemented with 10% heat-inactivated fetal calf serum (HI-FCS),

100g/ml penicillin and 100g/ml streptomycin (P/S). From day 7 through day 28, the
cultures will be fed every 48 hours with alpha-MEM, 10% HI-FCS, penicillin (100t/ml),

streptomycin (50gg/ml), and supplemented with 50tg/ml phosphoascorbate and 4mM 13-

glycerol phosphate.
The osteogenic capacity of these cells was assessed via visualization of both
mineralized bone nodules and GFP fluorescent of colonies under a microscope. The cell
colonies were imaged via phase/contrast and fluorescence microscopy on days 14, 17 and

21 at both 10x and 40x magnification. Additionally, the distribution and quantification of

GFP expression in the cell cultures was observed at the macroscopic level via a
fluorimager.
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Cell Proliferation." BrdU-APC

At days number 8, 10, an 12 the cultures were labeled with l mM BrdU (20 tl into
2ml well) and then incubated 120 minutes at 37C.
After washing the cultures with PBS two times, 0.5 ml of the following digestion
solution (30 ml of 2.5% trypsin, 300 mg of Collagenase A, 300 mg of Hyaluronidase)
was added to each well. Cultures were placed in 37 C incubator for 20 minutes.

Floating cells were then collected into 15 ml collecting tube (one tube per three wells).
Wells were rinsed with 2 ml of DMEM and then transferred to the same collecting tube.
Cells were collected by centrifugation. Supematants were removed and cells were

suspended in 2 ml of PBS. Then cells were filtered through a 35 gm strainer using a 10
ml syringe and collected into 15ml tube.

Once cells were harvested, using the BD Biosciences Pharmingen BrdU labeling
Kit, they were fixed with buffer 1 (BD Cytofix/Cytoperm Buffer), then permeabilized
with buffer 2 and buffer 3 (BD Perm/Wash Buffer, BD Cytoperm Plus Buffer), and later

treated with DNase for 1 hour at 37C to expose BrdU epitopes. Cells were then washed
and stained with an APC labeled anti-BrdU antibody. Negative controls had the BrdU

pulse omitted but were otherwise handled in an identical manner.
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BrdU Flow Cytometry Analysis

A calibur II machine was used for the flow cytometry analysis, a forward/side scatter
profile was obtained for each sample. BrdU was gated using the APC gate (FL-4) and

GFP was gated on FL-1. BrdU and GFP were plotted individually by the use of
histograms, and also BrdU was also plotted as a function of GFP. A quadrant plot was
used to measure the percentage of cells incorporating BrdU and GFP, these quadrant
were set up with the use of the control samples.

Cell Apoptosis. Annexin V

Primary calvarial cells will be cultured for 6 to 12 days and harvested as described above,
but without fixation or permeabilization. Cells were labeled with APC-conjugated
annexin V and 7-AAD, which in this context is used as a vital stain. No 7-AAD labeling

of DNA should be observed in intact cells.

Flow cytometry in this case involved

measurement of fluorescent signals in FL3 (7-AAD) and FL4 (annexin V), with

appropriate compensation for overlap. Using the combination of annexin V and 7-AAD
labeling allowed us to track the progress in cell death over time in culture, as cells

proceed from early apoptosis (annexin V labeling only) to later stages of apoptosis

(annexin V and 7-AAD labeling). Negative controls were provided by omission of
annexin V and/or 7-AAD from the labeling reaction.
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Flow Cytometry Analysis ofAnnexin-7AAD Labeling
The same machine used for BrdU incorporation was used to measure the amount of
annexin-7AAD labeling. Annexin V was measured using the APC gate (FL-4) and 7

AAD using the FL3 gate. A forward a side scatter was obtained for each sample.
Annexin V was plotted as function of 7AAD, and in very similar manner quadrants plots
were used to measure the percentages of cells labeled with annexin V and 7AAD.

Control samples were used to set up these quadrants. Since we observed some limitations
in the measuring of the annexin V positive labeling when the quadrants plots were used,
we decided to gate the area that was miss out on the quadrant plot, to measure the

annexin V positive cells, this area was name G1 gated annexin. To determine the type of

cells that were undergoing apoptosis, annexin V was plotted as a function of the forward
scatter, and subsequently quadrants plot were drawn as settled by control samples
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Significance

There is mounting evidence that C/EBP transcription factors are important

regulators of proliferation, cellular differentiation, and apoptosis. Previous studies using
a naturally-occurring dominant negative C/EBP transcription factor to broadly target
C/EBP function throughout the stromal-osteoblast lineage have unmasked both early and

late effects of this transcription factor family. Late inhibitory effects on and bone
formation and the expression of osteoblast-specific markers suggest that C/EBP function
is required for terminal osteoblast differentiation. Determining the molecular
mechanisms by which C/EBP regulates maturation of these cells will therefore enhance
our understanding of the transcriptional control of gene expression, cell morphology and

matrix elaboration in bone and in other mineralized tissues.

Osteoblasts play a significant role in bone growth, bone development and
orthodontic tooth movement. Osteoblastic differentiation from mesenchymal progenitor

cells is an extremely complex process. The precise molecular mechanisms behind it are
still largely unknown. Understanding the factors involved in the process of osteoblastic

differentiation could help eradicate skeletal diseases such as cleidocranial dysplasia,

osteoporosis, periodontitis and other diseases of bone. Additionally, comprehension of
the growth and activity of the osteoblast could lead to a better understanding of the
mechanism and rate of tooth movement in the field of orthodontics.

24

Results

Transgenic pOBCol3.6-FLp20 C/EBP[3 mice were crossed with homozygous

pOBCo13.6-GFP mice. The pOBCol3.6-GFP, provided an osteoblast-specific marker
which can be visualized and photographed in living cells under a microscope.

The cellular mechanisms regulating expansion of progenitors were assessed by

flow cytometry. The cellular autonomy of transgenic effects was assessed by the behavior
of GFP-positive and negative populations with respect to proliferation and apoptosis. The

experiments were done on the time period between 6 and 14 days of culture.
BrdU Incorporation
Cells were cultured from 8 to 14 days, and BrdU was pulsed from 2 to 12 hours.

The initial BrdU incorporation of study (experiment 253) was performed on day 8
(Figure 9 and 10), using a BrdU pulsed of 2 hours. Harvested cells were analyzed for

expression of GFP (FL 1) and incorporation of BrdU (FL4). The increased in cell number
at day 8 was associated with an increase in the percentage of GFP-positive cells. GFP

positive cells in TG cultures represent 33% of the total compared to 28% in WT cultures
consistent with expansion of the transgene-expressing population. (table I and II).

However, in this experiment we did not find differences in BrdU incorporation in the
GFP negative population (BrdU+/GFP-) between WT (WT mean, 9.31%) and TG cells

(TG mean 7.36%). Nor was any difference found in BrdU incorporation in the double
positive cells (BrdU+/GFP+), as shown by comparison of their mean values (WT,4.62

TG,3.61). (Tables I and II; Figure 11)
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The results for the BrdU incorporation using flow cytometry analysis on done on

day 10;( Figure 12) are consistent with those on day 8. Increased cell number at day 10
was also associated with an increase in the percentage of GFP-positive cells. Transgenic

GFP-positive cells represented a mean of 33% of the total cell population compared with.
22% in WT cultures (Table III, IV and Figure 14). In this experiment BrdU

incorporation in GFP negative cells (BrdU+/GFP-) was actually higher in WT cells

(Mean 4.53%) compared with their TG counterpart (mean 1.18%). Although BrdU
incorporation was higher in WT cultures this difference needs to be interpreted cautiously
due to the preliminary nature of this study and small sample size (n=2). Wild type
cultures also showed a modest increase in BrdU incorporation in the GFP positive cells.
The results of the BrdU incorporation on day 12 from the same experiment

(Figure 13), showed no increases in cell number or on the amount of GFP-positive cells.

TG cultures contained 24% GFP positive cells compared with. 21% in the WT group

(table V, VI; Figure 15). By day 12 BrdU incorporation was very low and did not differ
between WT (WT mean, 0.48%) and TG (TG mean, 0.17%) cells in the GFP negative

population

(BrdU+/GFP-). In the double positive cells, (BrdU+/GFP+) BrdU was extremely low
(0.15% labeling in WT) with no difference seen between WT and TG cells. (Tables V,
VI; Figure 15).
Since no positive results were obtained from the 2 hours BrdU pulse experiments,
it was decided to increase the time of pulsing, aiming to increase the chances of getting

cells going through the S phase of the cell cycle. The results for this experiment done on

day 9 (tables VII, VIII; Figures 16-18) were similar to those seem on the previous
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experiments, the BrdU incorporation on the GFP negative cells (BrdU+/GFP-) showed no
difference between the WT and TG cell cultures as seem by comparison of their mean

values, (Mean WT,5.56; TG, 5.07). In the double positive cells (BrdU+/GFP+), the WT
cells showed more BrdU incorporation than the TG cells, (Mean WT, 2.55; TG, 1.14),
but since the incorporation was very little and as mentioned previously a small sample
sized was used (n=3), these results should be interpreted cautiously. The number of GFP

positive cells on the WT group observed in this study was very similar to that observed
on the TG.

(Mean WT,24.9%; TG, 23.5%).

Interestingly even when small sample sizes were used and regardless of the BrdU

pulsing time, there was no evidence that showed increase BrdU incorporation in TG

cultures, that explained the increment in cell number. However examination of the
forward scatter/side scatter (FSC/SSC) plot showed a difference between WT and TG
cells. WT cells showed an increase in a population with high FSC and low SSC often
referred to as "scatter apoptotic" cells (Fig.9, 11 and 13 shaded circles), due to the fact
that cells undergoing programmed cell death often exhibit such a profile, indicative of
small cells exhibiting a high degree of granularity.

To determine whether there might be differences in apoptosis between WT and
TG cultures, cells were harvested and labeled with annexin V-APC and 7-AAD.
Annexin V binds to exposed phosphatidyl-serine on the plasma membrane of early

apoptotic cells, whereas 7-AAD binds to DNA of cells that have lost plasma membrane
integrity.

27

Annexin V Labeling

The results for annexin V incorporation between WT and TG cell cultures done on day 6

showed reduced Annexin V labeling on the TG group. (Figures 16,17 and Tables IX, X).
The mean annexin incorporation in the WT group (Annexin+/7AAD-) was 15.29 and in
the TG group this was only 5.49, representing a 3 fold difference. The double positive

cells showed higher incorporation in the WT group, while the 7AAD positive group
showed very little difference between the WT and TG groups.
The amount of annexin incorporation as seen by the G 1 gated annexin, was higher
on the WT group with a mean G annexin V labeling of 41% compared to the TG group

with 22% annexin labeling (figure 22).

The results for the plot between annexin V labeling and forward scatter on day 6

(Table XI and figure 23), showed a higher annexin V incorporation in the WT group for
the cells that have a low forward scatter (scatter apoptotic). Mean WT annexin labeling
was 15.95% compared to TG 5.28% in TG cells with low forward scatter, this was also

true for the cells with high forward scatter which likely represent early apoptotic cells

mean WT labeling in the high forward scatter population was 10.85% compared to

5.37% in the TG group. The TG cultures showed a higher number of cells with a high

forward scatter and no annexin incorporation (scatter viable cells), with a mean of 62.0%

compared to only 32.0% in the same population of WT cells.
The results for day 10 showed were very similar to those done on day 6, with the

TG group showing less annexin V labeling (figure 24-26;Table XII-XIII) The mean WT
annexin+/7AAD- was 4.70% whereas and in the TG group this was only 1.33%, this

time the difference was not as high as on day 6. The double positive cells showed very
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similar incorporation on the WT and TG group and the 7AAD positive group showed

higher incorporation on the TG group than the WT, but since the normal are so low, they
were not considered to be important.

The G 1 gated annexin results showed higher annexin incorporation in the WT

group than the TG, with a mean WT incorporation of 20% and a mean TG incorporation
of 9.5% (figure 27)
The analysis of annexin V labeling as a function of forward scatter on day 10

(Table XIV and figure 28), showed a higher annexin V labeling on the WT group for the
cells that have low forward scatter. (scatter apoptotic). Mean WT labeling was 2.0% of
the cells compared to 1% of the TG cells. This was also true for the cells with high

forward scatter (early apoptotic cells), with a mean WT incorporation of 4.5% compared
to 1.2% on the TG group. The TG cultures showed a higher number of cells with a high

forward scatter and no annexin labeling (scatter viable cells), with a mean of 70.5%

compared to 44.9% in the WT cultures.
The results of different experiments done on day 7 showed consistency with
those done on day 6 and 10 the TG group showed smaller annexin V labeling (figure 2931 and tables XV-VII) The Mean WT Annexin+/7AAD- was 13.67% and on the TG

group this was only 7.43 %, this was considered a significant difference between the two

groups. The double positive cells showed similar incorporation on both groups and the

7AAD positive group showed very little difference between the groups.
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The G 1 gated annexin results showed higher annexin labeling in the WT group than the

TG, with a mean WT annexin labeling of 23.2% compared to 21.5% in their TG
counterpart (figure 32).
The results of annexin V labeling as a function of forward scatter on day 7 (Table

XVII and Figure 33), showed a higher annexin V labeling in the WT group for the cells
that have a low forward scatter (scatter apoptotic), mean WT incorporation 9.55 %

compared to TG 7.45% and this was also true for the cells with high forward scatter
(early apoptotic cells) mean WT incorporation 15.45% compared to 7.4% on the TG
group. The TG cultures showed a higher number of cells with a high forward scatter and
no annexin V labeling (scatter viable

cells), with a mean of 37.85% compared to 30.46%

on the WT.

On the experiment done on day 7 (Figure 34) it was attempted to do a three color
analysis between annexin incorporation and GFP expression, but the lack of GFP control
and the possible spilled between channels made the analysis to difficult.
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Discussion

Preliminary studies done in our laboratory using femurs and calvaria of transgenic
mice indicated two possible sites of action at which p20C/EBP]3 affected the osteoblast

lineage. The first site of action occurred late in osteoblast differentiation, manifested as
observed by a decrease in terminal markers of osteoblastic differentiation such as
osteocalcin and POBCol2.3-GFP because the latter is a transgenic reporter of osteoblast

differentiation in which the visible GFP protein is expressed under control of a 2.3 kb

Cola l promoter construct. The second site appears to be in early osteoblast differentiation
characterized an increase in early differentiation markers such as BMP and alkaline

phosphatase. These preliminary studies have also shown an increase in cell number in
transgenic mouse stromal cells cultures.
The same phenomenon was observed on primary cell cultures, with an increase in
cell number in the TG cultures after day 7, reaching a plateau at day 15. It was unknown
if the increase in cell number in the TG cultures was due to an increase in cell

proliferation or a decrease in cell apoptosis. We hypothesized that primary osteoblast
from transgenic mice over expressing the p20C/EBP[3 would have an enhanced

proliferation when compared to WT cells.
There are numerous studies that suggest an antiproliferative effect of C/EBP]3 as
in hepatocytes and keratinocytes. [56, 57]. In contrast to these actions, C/EBPB seems to

be a positive regulator of the cell cycle in mammary epithelial cells [40, 41 ]. The

p20C/EBP dominant negative isoform has also been associated with hyperproliferation
and transformation in mammary epithelial cells[42].
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In the present study we used transgenic pOBCol3.6-FLp20 C/EBP[3 mice on a
pOBCoI3.6-GFP genetic background. GFP therefore served as a surrogate marker, for
the transgene, with the purpose of tracking the TG cells that were undergoing cell

replication. This approach allowed us to asses whether the p20C/EBP]3 transgene,
exerted cell autonomous effect on proliferation, BrdU was pulsed into the cultures to
label the cells that were going through S phase of the cell cycle, and the results were

analyzed using flow cytometry.
The results observed on day 8, showed no increase in BrdU incorporation in
either the GFP negative or positive TG cells populations. We expected to see differences
at this time point based on growth curves indicating the divergence of WT and TG cell

number during this phase of the cultures. Indeed BrdU incorporation was maximal at day

8, then tended to decrease on day 10 and day l 2, which was expected due to a decrease in
cell proliferation at later stages of the culture. At all the time points, BrdU incorporation
was lower in GFP positive when compared with the GFP negative population of cells).

This may be due to the more advanced differentiation stage of GFP positive cells when

compared with the GFP negative cell population.
The results for longer pulses (12 hours) of BrdU were analyzed and very similar
results were observed; no difference in the mean BrdU incorporation between WT and

TG cultures in either the GFP negative or positive populations. The prolonged pulse of
BrdU, given at the time of cells feeding, increased the likelihood labeling cells going

through the S phase of the cell cycle that might have been missed using a shorter pulse.
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It was observed that in both population groups (GFP negative and positive cells)
there was no evidence of increased BrdU incorporation in the TG cultures that would

explain the difference in cell number between the groups.
The increased cell number at day 8 was associated with an increase in the

percentage of GFP-positive cells, consistent with expansion of the transgene-expressing

population. This was also seen on at days 10 and 12, albeit with a smaller difference
between groups.

Although the cellular proliferation data were negative, examination of the forward
scatter/side scatter

(FSC/SSC) profile showed a difference in the cell distribution between

WT and TG cells. WT cells showed an increase in a population with high FSC and low
SSC often referred to as "scatter apoptotic" cells (Fig.9, 11 and 13 shaded circles),
because cells undergoing programmed cell death often exhibit a small size and high

degree of granularity. That led us to hypothesize that primary osteoblasts from transgenic
mice showed decreased apoptosis compared to wild type cells.

C/EBP[3 has been linked to enhance apoptosis in Neuro2Acell [44], but
contrasting these results, C/EBPI3 can also act as an inhibitor of apoptosis as has been
observed in keratinocytes, [56], and in hepatic stellate cells [46].

In our study to identify the number of cells undergoing programmed cell death a
7AAD-Annexin V incorporation assay was used followed by flow cytometry analysis in

order to measure labeling with these apoptotic markers. The results for annexin V

labeling for the experiments done on day 6, showed increased annexin labeling on the
annexin positive WT cultures compared to their counterpart in the TG group; very similar

results were observed when the experiments were done on day 7 and 10, with the TG
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cultures showing a two-three fold lower annexin labeling than the WT cultures. This is a

novel finding since no studies have been published using osteoblasts with over expression

p20C/EBPI3 to evaluate programmed cell death. The two-three fold difference found in
these experiments could explain the difference in cell number between the WT and the

TG group observed from day 7 to 15. For example, if we use a pure mathematical model
and spanning 5 cell doublings, a 10% increase in the apoptotic rate WT cells could
account for a two-fold increase in the total number of TG cells, compared to the WT

group.

An interesting observation was seen when the annexin V labeling was examined
as a function of forward scatter. Cells with smaller forward scatter had a higher labeling

of annexin V in the WT group. This result was seen on days 6, 7 and 10, and was

expected, since cells undergoing programmed cell death tend to decrease in size.

However, annexin labeling was also higher in the WT group in the cells with high
forward scatter, likely representing that are just starting to present apoptotic features.
Consistent with this interpretation annexin V binding to the phosphatidyl serine residues,
is known to be an early marker of apoptosis. The number of viable cells (no

annexinigh forward scatter) was higher in the TG group in all the experiments, which
led us to conclude that the p20C/EBPI3 could potentially increase the number of

pluripotent viable cells. These progenitors may then undergo either osteoblast or
adipogenic differentiation depending on the differentiation stimulus provided. Recent
studies in our laboratories have demonstrated enhanced adipocyte differentiation in TG

bone marrow stromal cells.
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In all of our experiments the amount of 7AAD labeling was extremely low in both
WT and TG cultures. We believe one of the possible reasons for these discrepancie might
be detachment of apoptotic cells from the tissue culture dishes when medium was

changed. The other possibility is that 7AAD is not a sufficiently sensitive marker to
measure apoptosis. In future experiments, propidium iodide will be used to determine

whether it provides better sensitivity for identification of late apoptotic cells.
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Conclusions

Overexpression of the p20C/EBPI3 transgene had no stimulatory effect on cellular

proliferation in early primary osteoblast cultures, as was seeing in our
experiments that did not show differences in the BrdU incorporation between the

WT and TG groups.

The p20C/EBP]3 appeared to inhibit apoptosis in early primary osteoblast cultures,
as observed by the 10% increase in apoptosis rate observed in the WT group

compared with their TG counterpart.

Transgenic overexpression of p20C/EBP]3 may regulate the availability of the
pluripotent osteoblast progenitor pool, explaining the increase in early osteoblast
markers (eg. AP and BSP) seen in TG cells

C/EBP transcription factors may regulate survival of multipotent mesenchymal

progenitor cells
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Legend of Tables and Figures
Table I Shows the raw data obtained on an experiment done on day 8. BrdU
incorporation and GFP expression were evaluated on WT and TG cultures
Table II Shows the results of experiments done on day 8. As can be observed no
difference was found in the mean BrdU incorporation between WT and TG
cultures
TablellI- Shows the raw data obtained on an experiment done on day 10. BrdU
incorporation and GFP expression were evaluated on WT and TG cultures

Table IV Shows the results of experiments done on day 10. As can be observed no
difference was found in the mean BrdU incorporation between WT and TG
cultures
Table V Shows the raw data obtained on an experiment done on day 12. BrdU
incorporation and GFP expression were evaluated on WT and TG cultures
Table VI Shows the results of experiments done on day 12. As can be observed no
significant difference was found in the mean BrdU incorporation between WT
and TG cultures

Table VII Shows the raw data obtained on an experiment done on day 9. BrdU
incorporation and GFP expression were evaluated on WT and TG cultures

Table VIII Shows the results of experiments done on day 9. As can be observed no
significant difference was found in the mean BrdU incorporation between WT
and TG cultures
Table IX "Shows the raw data obtained on an experiment done on day 6. Annexin V and
7 AAD were evaluated on WT and TG cultures
Table X Shows the results of experiments done on day 6. As can be observed difference
was found in the mean Annexin V incorporation between WT and TG cultures
Table XI Shows the results obtained from the annexin vs forward scatter in experiment
done on day 6.
Table XII Shows the data obtained on an experiment done on day 10. Annexin V and
7AAD labeling were evaluated on WT and TG cultures

Table XIII Shows the results of experiments done on day 10. As can be observed
significant difference was found in the mean Annexin V incorporation between
WT and TG cultures
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Table XIV Shows the results obtained from the annexin vs forward scatter in experiment
done on day 10.

Table XV Shows the raw data obtained on an experiment done on day 7. Annexin V and
7AAD labeling were evaluated on WT and TG cultures
Table XVI Shows the results of experiments done on day 7. As can be observed
significant difference was found in the mean Annexin V incorporation between
WT and TG cultures
Table XVII Shows the results obtained from the annexin vs forward scatter in
experiment done on day 7.
Table XVIII Shows the data obtained on an experiment done on day 7. Annexin V
labeling and GFP expression were evaluated on WT and TG cultures
Table XIX Shows the results of experiments done on day 7. As can be observed
significant difference was found in the mean Annexin V incorporation between
WT and TG cultures

Fig. 1 Lifecycle of an osteoblast: Osteoblast precursors are recruited from a
multipotential mesenchymal progenitor that can give rise to several differentiated
cell phenotypes including fibroblasts, chondrocytes, adipocytes and osteoblasts.
Undifferentiated osteoprogenitors are present in the bone marrow and periosteum.
These undifferentiated osteoprogenitor cells eventually differentiate into
preosteoblasts, osteoblasts and finally osteocytes
Fig. 2 Schematic representation of the Leucine zipper

Fig. 3 C/EBPI3 mRNA encodes multiple isoforms by alternative trans-lational initiation from
multiple AUG start sites. Major isoforms include a 35-kd transcriptional activator
and a 20-kd dominant negative inhibitor.
Fig. 4 Showed the two possible action sites for C/EBP]3 on the osteoblast differentiation as
seen by an increase in early markers observed during the normal osteoblast, pOBCol
3.6-GFP and alkaline phosphatase and a decrease in late markers such as POBCol2.3GFP and osteocalcin.

Fig 5. Growth of primary calvarial cells is increased in TG cultures after day 7
Fig. 6 BrdU is incorporated into newly synthesized DNA by cells entering and
progressing through the S phase (DNA synthesis) of the cells cycle. The
incorporated BrdU is stained with specific anti-BrdU fluorescent antibodies.

Fig. 7 Schematic represemation of Annexin V incorporation to the cytoplasmic
membrane, as can be seen in Figure 4A it would not incorporate on normal cells,
but it will incorporate to cells on the early stage of apoptosis on which
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translocation of the membrane phospholipids phophatidylserine (PS) from the
inner to the outer leaflet of the plasma membrane has occurred. (Figure 4B)

Fig. 8 Schematic representation of 7AAD incorporation to the nuclear DNA at later
stages of apoptosis, once the cytoplasmic membrane has been disrupted.

Fig. 9 Analysis of proliferation by flow cytometry at day 8 in representative WT and TG
samples. Forward scatter-side scatter plots (left plot in each panel) showed a
reduction in "scatter apoptotic" (low FSC/high SSC) cells in TG cultures
(compare yellow shaded circles). In quadrant plots (right plot in each panel), Xaxis (FL1) represents GFP, Y-axis (FL4) is BrdU incorporation. Numbers
represent the percentage of cells in each quadrant. TG cultures showed an
increase in GFP-positive cells (mean 33% vs. 28% in WT). No significant
differences in BrdU incorporation were seen in this experiment.
Fig. 10 Analysis of proliferation by flow cytometry at day 8 in representative control
samples. In quadrant plots (right plot in each panel), X-axis (FL 1) represents
GFP, Y-axis (FL4) is BrdU incorporation. Numbers represent the percentage of
cells in each quadrant.
Fig. 11 BrdU incorporation and GFP expression in day 8, WT and TG cultures. As can be
seen no difference exist on the BrdU incorporation between WT and TG cultures.
But it can be observed an increase in the amount of GFP positive cells on the TG
(33%) cultures vs WT (28%).
Fig. 12 Analysis of proliferation by flow cytometry at day 10 in representative WT and
TG samples. Forward scatter-side scatter plots (left plot in each panel) showed a
reduction in "scatter apoptotic" (low FSC/high SSC) cells in TG cultures
(compare yellow shaded circles). In quadrant plots (right plot in each panel), Xaxis (FL 1) represents GFP, Y-axis (FL4) is BrdU incorporation. Numbers
represent the percentage of cells in each quadrant. TG cultures showed an
increase in GFP-positive cells (mean 33% vs. 22% in WT). No differences in
BrdU incorporation were seen in this experiment.

Fig. 13 BrdU incorporation and GFP expression on WT and TG cultures on day 12. BrdU
incorporation was higher on the WT cultures on the GFP positive and negative
cells, but not considered to be significant due to hight standard error and very low
incorporation. TG cultures showed a small increase in GFP positive (24%) cells
vs WT cultures (21%)

Fig. 14 BrdU incorporation and GFP expression in WT and TG cultures on day 10. WT
cells showed an increase in BrdU incorporation in the GFP positive and negative
cells compared to TG cultures, but not considered significant due to high stardard
error between samples. TG cultures showed an increase in GFP positive (32%)
cells compared to WT cultures (19%)
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Fig. 15 Analysis of proliferation by flow cytometry at day 12 in representative WT and
TG samples. Forward scatter-side scatter plots (left plot in each panel) showed a
reduction in "scatter apoptotic" (low FSC/high SSC) cells in TG cultures
(compare yellow shaded circles). In quadrant plots (right plot in each panel), Xaxis (FL 1) represents GFP, Y-axis (FL4) is BrdU incorporation. Numbers
represent the percentage of cells in each quadrant. TG cultures showed a decrease
in GFP-positive cells (mean 18% vs. 21% in WT). No significant differences in
BrdU incorporation were seen in this experiment.
Fig. 16 Analysis of proliferation by flow cytometry at day 9 in representative WT and TG
control samples. Forward scatter-side scatter plots (left plot in each panel)
showed a reduction in "scatter apoptotic" (low FSC/high SSC) cells in TG
cultures (compare yellow shaded circles). In quadrant plots (right plot in each
panel), X-axis (FL 1) represents GFP, Y-axis (FL4) is BrdU incorporation.
Numbers represent the percentage of cells in each quadrant.
Fig. 17 Analysis of proliferation by flow cytometry at day 9 in representative WT and
TG samples. Forward scatter-side scatter plots (left plot in each panel) showed a
reduction in "scatter apoptotic" (low FSC/high SSC) cells in TG cultures
(compare yellow shaded circles). In quadrant plots (right plot in each panel), Xaxis (FL 1) represents GFP, Y-axis (FL4) is BrdU incorporation. Numbers
represent the percentage of cells in each quadrant. TG cultures showed a decrease
in GFP-positive cells (mean 23.5% vs. 24.8% in WT). No significant differences
in BrdU incorporation were seen in this experiment.
Fig. 18 BrdU incorporation and GFP expression on WT and TG cultures on day 9. WT
cells showed an increase in BrdU incorporation in the GFP positive and negative
cells compared to TG cultures, but not considered significant due to high stardard
error between samples. TG cultures showed similar expression of GFP positive
cells (23.5) compared to WT cultures (24.8%).
Fig. 19 A negative control without annexin-V-APC from experiment 329 day 6. The
polygon on the upper diagrams represent the G 1 gated annexin. On the lower left
can be seen the plot from the forward vs side scatter, and the lower right shows
the annexin vs forward scatter
Fig 20 Analysis of apoptosis by flow cytometry in replicate day 6 WT and TG cultures.
Labeling was performed with annexin V-APC (FL4; Y axis) and 7-AAD (FL3; X
axis) to visualize early and late apoptotic cells. Numbers represent the percentage
of cells in each quadrant. These data indicate that early WT cultures contain a
higher percentage of annexin V labeling than TG cultures. The polygon represents
the G 1 gated annexin, as settled by controls. The lower left diagrams show the
forward and side scatter plot from both samples, and the lower right diagrams
show the annexin vs forward scatter as can be seen WT cultures have higher
annexin V incorporation than TG cultures, in cells with high and low forward
scatter
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Fig. 21 Annexin V and 7-AAD labeling in WT and TG cultures on day 6. WT cultures
incorporated more annexin V than TG cultures. Very low number can be seen
from the double positive cells and 7AAD positive cells

Fig. 22 Annexin V labeling on WT and TG cultures on day 6 as obtained from G1 gated
annexin. As can be seen WT cultures incorporated higher amounts of annexin V
than TG cultures.
Fig. 23 Annexin V incorporation expressed as a function of forward scatter in WT and
TG cultures on day 6. WT cultures incorporated higher amounts of annexin V on
the low forward scatter (scatter apoptotic) and high scatter (early apoptotic) than
TG cultures. TG cultures show a higher amount of cells with no annexin and high
forward scatter (scatter viable cells)
Fig.24 A negative control without annexin-V-APC from experiment 329. The polygon
on the upper diagrams represent the G 1 gated annexin. On the lower left can be
seen the plot from the forward vs side scatter, and the lower right shows the
annexin V incorporation expressed as function of the forward scatter

Fig. 2; Analysis of apoptosis by flow cytometry in replicate day 10 WT and TG cultures.
Labeling was performed with annexin V-APC (FL4; Y axis) and 7-AAD (FL3; X
axis) to visualize early and late apoptotic cells. Numbers represent the percentage
of cells in each quadrant. These data indicate that early WT cultures contain a
higher percentage of annexin V labeling than TG cultures. The polygon represents
the G1 gated annexin, as settled by controls. The lower left diagrams show the
forward and side scatter plot from both samples, and the lower right diagrams
show the annexin expressed as function of the forward scatter as can be seen WT
cultures have higher annexin V incorporation than TG cultures, in cells with high
and low forward scatter.
Fig. 26 Annexin V and 7-AAD labeling in WT and TG cultures on day 10. Annexin V
and 7AAD labeling were evaluated on WT and TG cultures. WT cultures
incorporated more annexin V than TG cultures. Very low number can be seen
from the double positive cells and 7AAD positive cells.

Fig. 27 Annexin V labeling in WT and TG cultures on day 10 as obtained by the G 1
gated annexin. As can be seen WT cultures incorporated higher amounts of
annexin V than TG cultures.
Fig. 28 Annexin V labeling expressed as a function of the forward scatter in WT and TG
cultures on day 10. WT cultures incorporated higher amounts of annexin V on the
low forward scatter (scatter apoptotic) and high scatter (early apoptotic) than TG
cultures. TG cultures show a higher amount of cells with no annexin and high
forward scatter (scatter viable cells)
Fig. 29 A negative control without annexin-V-APC from experiment done on day 7. The
polygon on the upper diagrams represent the G1 gated annexin. On the lower left
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can be seen the plot from the forward vs side scatter, and the lower right shows
the annexin vs forward scatter

Fig. 3tl Analysis of apoptosis by flow cytometry in replicate day 7 WT and TG cultures.
Labeling was performed with annexin V-APC (FL4; Y axis) and 7-AAD (FL3; X
axis) to visualize early and late apoptotic cells. Numbers represent the percentage
of cells in each quadrant. These data indicate that early WT cultures contain a
higher percentage of annexin V labeling than TG cultures. The polygon represents
the G1 gated annexin, as settled by controls. The lower left diagrams show the
forward and side scatter plot from both samples, and the lower right diagrams
show the annexin vs forward scatter as can be seen WT cultures have higher
annexin V incorporation than TG cultures, in cells with high and low forward
scatter.

Fig.31 Annexin V and 7 AAD labeling in WT and TG cultures on day 7. WT cultures
incorporated more annexin V than TG cultures. Very low number can be seen
from the double positive cells and 7AAD positive cells
Fig. 32 Annexin V labeling in WT and TG cultures on day 7 as obtained by G1 gated
annexin. As can be seen WT cultures incorporated higher amounts of annexin V
than TG cultures.
Fig. 33 Annexin V expressed as a function of forward scatter in WT and TG cultures on
day 7. WT cultures incorporated higher amounts of annexin V on the low
forward scatter (scatter apoptotic) and high scatter (early apoptotic) than TG
cultures. TG cultures show a higher amount of cells with no annexin and high
forward scatter (scatter viable cells)
34
Fig. Analysis of apoptosis by flow cytometry in replicate day 7 WT and TG cultures.
Labeling was performed with annexin V-APC (FL4; Y axis) and GFP (FL 1; X
axis) to visualize early and late apoptotic cells. Numbers represent the percentage
of cells in each quadrant. These data indicate that early WT cultures contain a
higher percentage of annexin V labeling than TG cultures
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Tables and Figures

BrdU-/GFP-

BrdU-/GFP+

BrdU+/GFP-

BrdU+/GFP+

WT

57.1

32.4

7.54

2.89

WT2

56.2

25.6

11.8

6.34

TG1

53.2

33.2

9.19

4.38

TG2

49.1

42.9

5.54

2.84

TGcx

63.3

34.5

1.78

0.47

Table I
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MEAN

MEDIAN

SoEo
0.45

WT BrdU-/GFP-

56.65

0.64

56.65

WT BrdU-/GFP+

29

4.81

29

WT BrdU+/GFP-

9.31

WT BrdU+/GFP+

4.62

TG BrdU-/GFP-

9.31

1.77

2.44

4.62

1.73

51.2

2.83

51.2

TG BrdU-/GFP+

38.05

6.86

38.05

4.85

TG BrdU+/GFP-

7.37

2.58

7.37

1.83

TG BrdU+/GFP+

3.61

1.09

3.61

0.77

Table II
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BrdU-/GFP-

BrdU-/GFP+

BrdU+/GFP-

WT

74.3

21.3

3.42

WT2

76

16.8

5.63

TG1

67.5

31

1.13

TG2

65.2

33.2

1.23

Table III
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BrdU+/GFP+

0.36

MEAN

MEDIAN

SoEo

WT BrdU-/GFP-

75.15

75.15

0.85

WT BrdU-/GFP+

19.05

3.18

19.05

2.25

WT BrdU+/GFP-

4.53

1.56

4.53

1.11

WT BrdU+/GFP+ 1.25

0.49

1.25

0.35

TG BrdU-/GFP-

66.35

1.63

66.35

1.15

TG BrdU-/GFP+

32.1

1.56

32.1

1.1

TG BrdU+/GFP-

1.18

0.07

1.18

0.05

TG BrdU+/GFP+

0.38

0.03

0.38

0.02

Table IV
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BrdU-/GFP-

BrdU-/GFP+

BrdU//GFP-

BrdU+/GFP+

WT

77.6

21.9

0.39

0.14

WT2

79.3

19.9

0.57

0.15

TG1

77.3

22.4

0.25

0.089

TG2

75

24.8

0.098

0.088

Table V
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MEDIAN

MEAN

SoEo

WT BrdU-/GFP-

78.6

1.41

78.6

WT BrdU-/GFP+

20.9

1.41

20.9

WT BrdU//GFP-

0.48

0.13

0.48

0.09

WT BrdU+/GFP+

0.15

0.007

0.15

0.005

TG BrdU-/GFP-

76.15

1.63

76.15

1.15

TG BrdU-/GFP+

23.6

TG BrdU+/GFP-

0.17

0.11

0.17

0.08

TG BrdU+/GFP+

0.08

0.006

0.08

0.004

23.6

Table VI
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BrdU-/GFP-

BrdU-/GFP+

BrdU+/GFP-

BrdU+/GFP+

WT

57.1

32.4

7.54

2.89

WT2

56.2

25.6

11.8

6.34

WT3

54.3

28.4

TG1

53.2

33.2

9.19

4.38

TG2

49.1

42.9

5.54

2.84

TG3

52.1

38.3

5.38

3.32

TGcx

63.3

34.5

1.78

0.47

Table VII
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Mean

Median

Soe.

WT BrdU-/GFP-

66.975

11.4996

62.9

5.74998

TG BrdU-/GFP-

71.3

9.82174

66.8

4.91087

WT BrdU-/GFP+

24.9

10.06512

28

5.03256

TG BrdU-/GFP+

22.5

8.51391

25.25

4.25696

WT BrdU+/GFP-

5.56

1.0202

0.5101

TG BrdU+/GFP-

5.075

2.81384

1.40692

WT BrdU+/GFP+

2.555

1.22911

2.98

0.61455

TG BrdU+/GFP+

1.1425

0.4731

1.275

0.23655

Table VIII
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ANN-/7AAD-

ANN-/7AAD+

ANN+/7AAD-

ANN+/7AAD+

WT

85.5

0.69

12.08

1.02

WT2

78.9

0.64

18.5

1.99

TG1

94

0.73

TG2

92.2

0.15

7.08

0.57

CX

98.8

1.37

0.09

0.26

1.42

Table IX

55

MEDIAN

MEAN

WT ANN-/ADD-

82.2

4.66

82.2

WT ANN-/ADD+

0.38

0.44

0.377

0.31

WT ANN+/ADD-

15.29

4.54

15.29

3.21

WT ANN+/ADD+

0.69

0.485

TG ANN-/ADD-

93.1

1.27

93.1

TG ANN-/ADD+

0.44

0.41

0.44

0.29

TG ANN+/ADD-

5.49

2.24

5.49

1.59

TG ANN+/ADD+

0.99

0.99

0.43

Table X
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MEDIAN

MEAN

SoEo

WT LOFSC/ANN-

37.9

1.27

37.9

TG LOFSC/ANN-

27.3

0.98

27.3

WT LOFSC/ANN+

15.95

5.16

15.95

TG LOFSC/ANN+

5.28

0.98

5.28

WT HIFSC/ANN+

10.85

0.49

10.85

0.35

TG HIFSC/ANN+

5.37

0.62

5.37

0.44

WT HIFSC/ANN-

35.35

4.45

35.35

3.15

TG HIFSC/ANN-

62.05

0.63

62.05

0.45

Table XI
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3.65

ANN-/7AAD-

ANN-/7AAD+

WT

90.8

0.19

WT2

95.8

0.17

WT3

98.2

TG1

97.8

0.33

1.69

TG2

98.7

0.36

0.74

TG3

97.9

0.3

1.58

0.18

WTc

99.7

0.24

0

0.05

ANN+/7AAD-

ANN+/7AAD+

0.44
3.97

0.08

1.55

Table XII
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0.23

MEDIAN

MEAN

WT ANN-/ADD-

94.93

WT ANN-/ADD+

0.12

WT ANN+/ADD-

4.71

WT ANN+/ADD+

0.21

T G ANN-/ADD-

98.13

0.49

97.9

0.28

TG ANN-/ADD+

0.33

0.03

0.33

0.02

TG ANN+/ADD-

1.34

0.52

1.58

TG ANN+/ADD+

3.77

3.58

95.8

2.18

0.17

0.01

3.97

2.01
0.12

0.03

Table XIII

59

0.01

Mean

Median

Soe,

WT LOFSC/ANN-

25.06

24.8

1.85

TG LOFSC/ANN-

27.13

2.47

26.7

1.43

WT LOFSC/ANN+

2.03

1.48

2.06

0.85

TG LOFSC/ANN+

1.07

0.63

WT HIFSC/ANN+

4.53

3.32

8.35

1.91

TG HIFSC/ANN+

1.22

0.13

1.26

0.07

WT HIFSC/ANN-

44.99

36.98

66.1

21.35

TG HIFSC/ANN-

70.5

70.3

1.73

Table XIV

60

0.36

ANN-/7AAD-

ANN-/7AAD+

ANN+/7AAD-

ANN+/7AAD+

WT

81.7

1.54

15.2

1.53

WT2

85.2

2.38

10.3

2.11

WT3

81.2

2.03

15.5

1.31

TG1

85.1

3.59

8.73

2.54

TG2

92.8

0.41

6.14

0.61

CX

99.5

0.16

0.19

0.19

Table XV

61

MEAN

MEDIAN

WT ANN-/ADD-

82.7

2.17

81.7

1.26

WT ANN-/ADD+

1.98

0.42

2.03

0.24

WT ANN+/ADD-

13.67

2.92

15.2

1.69

WT ANN+/ADD+

1.65

0.41

1.53

0.24

TG ANN-/ADD-

88.95

5.44

88.95

3.85

TG ANN-/ADD+

1.59

2.25

TG ANN+/ADD-

7.44

1.83

7.44

TG ANN+/ADD+

1.58

1.36

1.58

Table XVI

62

0.97

Mean

Median

Soeo

WT LOFSC/ANN-

37.56

3.36

36.2

1.94

TG LOFSC/ANN-

51.95

21.42

51.95

15.15

WT LOFSC/ANN+

9.55

1.82

10.4

1.05

TG LOFSC/ANN+

7.45

1.56

7.45

1.11

WT HIFSC/ANN+

15.46

1.15

14.9

0.66

TG HIFSC/ANN+

9.73

6.88

9.73

4.87

WT HIFSC/ANN-

30.46

5.25

39.5

3.03

TG HIFSC/ANN-

37.85

16.05

30.85

11.35

Table XVII

63

ANN-/GFP-

ANN-/GFP+

ANN+/GFP-

ANN+/GFP+

WT

67.2

17.5

11.7

3.64

WT2

70.5

18

8.02

3.54

WT3

71.4

11.8

12.7

4.13

TG1

55.4

33.3

5.96

5.31

TG2

86.6

6.59

5.23

1.53

CX

82.6

17.1

0.12

0.25

Table XVIII

64

Mean

Median

Soe.

WT ANN-/GFP-

69.7

2.21

70.5

1.28

WT ANN-/GFP/

15.77

3.44

17.5

1.99

WT ANN+/GFP-

10.81

2.46

11.7

1.42

WT ANN+/GFP+

3.77

0.32

3.64

0.18

TG ANN-/GFP-

71

22.06

71

15.6

TG ANN-/GFP+

19.95

18.89

19.95

13.6

TG ANN+/GFPTG ANN+/GFP+

0.52
3.42

2.67

Table XIX

65

0.37

3.42

1.89

Expt297: Growth Curve
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